Thyroid

Hashimoto's Thyroiditis

search

Hashimoto's Thyroiditis, Hashimoto's Disease, Hashimoto Thyroiditis, Chronic Lymphocytic Thyroiditis, Chronic Autoimmune Thyroiditis, Askenazy Cell, Hurthle Cell

  • Epidemiology
  1. More common in women than men by 3-7 fold
  2. Age of onset peaks at 40-60 years
  3. Increased risk with Family History of autoimmune Thyroid disease
  4. Incidence: 0.3 to 1.5 cases per 1000 persons per year (U.S.)
    1. Most common Autoimmune Disease worldwide
  5. Prevalence of Antithyroid Antibody
    1. Total population: 3-4%
    2. Euthyroid asymptomatic adolescents: 1.4%
    3. Middle aged to elderly women: 30-40%
  • Pathophysiology
  1. Chronic autoimmune Thyroid inflammation
  2. Thyroid infiltration by Lymphocytes as well as Thyroid fibrosis
  3. Results in formation of Askanazy cells (Hurthle Cells)
  1. Excess Iodide intake
  2. Tobacco Abuse (thiocyanate exposure)
  • Symptoms
  1. See Hypothyroidism
    1. May initially experience Hyperthyroidism (rarely, hashitoxicosis)
    2. Generalized Fatigue
    3. Weight gain
    4. Cold intolerance
    5. Diffuse myalgias
  2. Painless Thyroiditis (painful in rare cases)
    1. However neck fullness (Goiter) Sensation is common
    2. Dysphagia may occur (from Goiter related compression)
  • Signs
  1. Hypothyroidism
    1. Rarely Thyrotoxicosis occurs due to the Thyroid Autoantibody stimulating effects
  2. Thyroid Goiter (90% of cases)
    1. Symmetric, diffusely enlarged, non-tender Thyroid
    2. Firm, irregular Thyroid surface
    3. Goiter is absent in atrophic form in which fibrosis dominates (with overt Hypothyroidism)
  • Labs
  1. Antithyroid Antibody
    1. Antithyroid Microsomal Antibody (Thyroid Peroxidase Antibody or TPO Antibody)
      1. Present in up to 90-95% of Hashimoto cases (and most specific if significantly elevated)
      2. More mild elevations of TPO Antibody are seen with other thyroid Autoimmunity
        1. Examples: Postpartum Thyroiditis, Silent Thyroiditis, Subacute Thyroiditis
    2. Antithyroglobulin Antibody are increased in 60-80% of patients
    3. TSH-receptor blocking Antibody may be present
  2. Thyroid function stepwise change
    1. First: TSH rises
    2. Next: T4 declines
    3. Next: T3 decline
    4. Last: Symptomatic Hypothyroidism
  • Management
  1. TSH >10 mU/L
    1. Levothyroxine starting at 1.6 mcg/kg/day in young, healthy patients
    2. Indications for Levothyroxine starting at low dose (12.5 to 25 mcg/day)
      1. Elderly
      2. Underlying Coronary Artery Disease
      3. Tachydysrhythmias
    3. Recheck Serum TSH every 10-12 weeks
  2. TSH 4.5 to 10 mU/L
    1. Pregnancy: Levothyroxine
      1. See Hypothyroidism in Pregnancy for dosing and monitoring frequency
    2. Other: Variable recommendations on whether to treat
      1. Consider treatment for positive TPO Antibody and Hypothyroidism symptoms
      2. If treated
        1. Start Levothyroxine 25 to 50 mcg daily
        2. Recheck Serum TSH in 10-12 weeks
      3. If not treated
        1. Recheck Serum TSH for overt Hypothyroidism in 6-12 months
  • Course
  1. Initially metabolically normal
  2. Later Thyroid failure usually ensues
  3. Thyroid Goiter and symptoms typically resolve by 6 months after becoming euthyroid on replacement
  1. Primary Thyroid Lymphoma (80 fold increased risk)
    1. Presents as rapidly growing Thyroid Nodule
    2. FNA Thyroid Nodule
  2. Papillary Carcinoma